NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Price Target & More

$9.32 -0.63 (-6.33 %)
(As of 04/24/2018 01:54 PM ET)
Previous Close$9.95
Today's Range$9.23 - $10.04
52-Week Range$6.10 - $16.20
Volume87,094 shs
Average Volume135,747 shs
Market Capitalization$110 million
P/E Ratio-1.98
Dividend YieldN/A
Beta1.58

About Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals logoEiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138

Debt

Debt-to-Equity Ratio0.58%
Current Ratio5.85%
Quick Ratio5.85%

Price-To-Earnings

Trailing P/E Ratio-1.98
Forward P/E Ratio-2.21
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book4.36

Profitability

EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-196.04%
Return on Assets-101.44%

Miscellaneous

Employees16
Outstanding Shares10,530,000

How to Become a New Pot Stock Millionaire

Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) issued its earnings results on Monday, March, 12th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.02) by $0.09. View Eiger Biopharmaceuticals' Earnings History.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Eiger Biopharmaceuticals.

What price target have analysts set for EIGR?

7 brokers have issued 1 year price targets for Eiger Biopharmaceuticals' stock. Their forecasts range from $17.00 to $35.00. On average, they expect Eiger Biopharmaceuticals' share price to reach $29.00 in the next twelve months. View Analyst Ratings for Eiger Biopharmaceuticals.

What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (3/22/2018)
  • 2. Wedbush analysts commented, "The Wedbush View: With four drug candidates being tested in four indications and enough cash runway to cover data readouts over the next 12 months, we believe EIGR is trading at an attractive value and recommend shares to investors." (6/21/2017)

Who are some of Eiger Biopharmaceuticals' key competitors?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the folowing people:
  • Mr. David A. Cory R.Ph, MBA, Pres, CEO, Director & Bus. Founder (Age 54)
  • Dr. Jeffrey S. Glenn M.D., Ph.D., Founder, Scientific Advisor & Director (Age 55)
  • Dr. Joanne M. J. Quan M.D., Chief Medical Officer (Age 54)
  • Mr. James P. Shaffer MBA, Chief Bus. Officer (Age 51)
  • Mr. James A. Welch MBA, Chief Financial Officer (Age 60)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

News coverage about EIGR stock has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eiger Biopharmaceuticals earned a news impact score of 0.03 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.08 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $9.32.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $110 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 350 CAMBRIDGE AVENUE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]


MarketBeat Community Rating for Eiger Biopharmaceuticals (EIGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eiger Biopharmaceuticals (NASDAQ:EIGR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Eiger Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 211.16%. The high price target for EIGR is $35.00 and the low price target for EIGR is $17.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$29.00$33.00
Price Target Upside: 211.16% upside205.26% upside81.25% upside194.64% upside

Eiger Biopharmaceuticals (NASDAQ:EIGR) Consensus Price Target History

Price Target History for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ:EIGR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018WedbushLower Price TargetOutperform$36.00 -> $34.00HighView Rating Details
3/21/2018OppenheimerReiterated RatingBuyHighView Rating Details
1/16/2018Piper JaffrayReiterated RatingOverweight$35.00 -> $17.00HighView Rating Details
1/3/2018Ladenburg ThalmannInitiated CoverageBuy -> Buy$32.00HighView Rating Details
10/19/2017Roth CapitalInitiated CoverageBuy -> Buy$35.00N/AView Rating Details
7/14/2017BTIG ResearchInitiated CoverageBuy$32.00HighView Rating Details
5/15/2017Jefferies GroupReiterated RatingBuy$28.00 -> $27.00MediumView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Eiger Biopharmaceuticals (NASDAQ:EIGR) Earnings History and Estimates Chart

Earnings by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ:EIGR) Earnings Estimates

2018 EPS Consensus Estimate: ($4.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.12)($0.87)($1.02)
Q2 20183($1.19)($0.86)($1.01)
Q3 20183($1.26)($0.85)($1.02)
Q4 20183($1.51)($0.84)($1.08)

Eiger Biopharmaceuticals (NASDAQ EIGR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018($0.96)N/AView Earnings Details
3/12/2018Q4 2017($1.02)($1.11)ViewN/AView Earnings Details
11/9/2017Q3 2017($1.28)($1.10)ViewN/AView Earnings Details
8/14/2017Q2 2017($1.2840)($1.33)ViewN/AView Earnings Details
5/12/2017Q1 2017($1.35)($1.34)ViewN/AView Earnings Details
3/23/2017Q4 2016($1.3830)($1.53)ViewN/AView Earnings Details
11/8/2016Q3 2016($1.21)($1.49)ViewN/AView Earnings Details
8/10/2016Q2($1.17)($1.87)ViewN/AView Earnings Details
5/16/2016Q1($1.69)($10.42)ViewN/AView Earnings Details
11/9/2015Q3 2015($3.30)($4.05)ViewN/AView Earnings Details
8/11/2015Q2($0.32)($0.69)ViewN/AView Earnings Details
5/14/2015Q1 2015($6.90)($10.64)ViewN/AView Earnings Details
3/31/2015Q414($0.36)($0.49)ViewN/AView Earnings Details
11/12/2014Q3 2014($0.39)($0.40)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.39)($0.38)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.44)($0.58)ViewN/AView Earnings Details
3/31/2014Q4 2013($0.47)($7.96)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Eiger Biopharmaceuticals (NASDAQ:EIGR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.80%
Institutional Ownership Percentage: 69.22%
Insider Trading History for Eiger Biopharmaceuticals (NASDAQ:EIGR)
Institutional Ownership by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Joanne QuanInsiderSell4,000$10.00$40,000.004,000View SEC Filing  
9/1/2017Jeffrey S GlennDirectorBuy15,000$9.53$142,950.0031,355View SEC Filing  
11/18/2016Jeffrey S GlennDirectorBuy15,460$12.74$196,960.4016,355View SEC Filing  
8/18/2016James P ShafferInsiderBuy3,125$15.70$49,062.505,620View SEC Filing  
8/18/2016Ventures Fund Vi L.P. VivoMajor ShareholderBuy187,500$16.00$3,000,000.00View SEC Filing  
6/22/2016James H WelchCFOBuy2,500$19.80$49,500.002,000View SEC Filing  
6/13/2016James P ShafferInsiderBuy1,250$22.17$27,712.501,975View SEC Filing  
5/23/2016James P ShafferInsiderBuy1,245$19.80$24,651.00500View SEC Filing  
4/6/2015Krisztina M ZseboCEOSell47,931$18.20$872,344.20View SEC Filing  
4/2/2015Rebecque J LabaVPSell11,012$17.30$190,507.60View SEC Filing  
3/9/2015Krisztina M ZseboCEOSell47,931$24.80$1,188,688.80View SEC Filing  
3/6/2015Peter HonigDirectorSell9,700$23.74$230,278.00View SEC Filing  
3/6/2015Rebecque J LabaVPSell14,000$23.06$322,840.00View SEC Filing  
3/2/2015Ryan K TakeyaVPSell7,777$18.48$143,718.96View SEC Filing  
2/9/2015Krisztina M ZseboCEOSell47,931$15.86$760,185.66View SEC Filing  
2/6/2015Rebecque J LabaVPSell14,000$16.08$225,120.00View SEC Filing  
2/2/2015Ryan K TakeyaVPSell7,777$16.35$127,153.95View SEC Filing  
1/9/2015Jeffrey J RudyVPSell10,000$18.51$185,100.00View SEC Filing  
1/7/2015Rebecque J LabaVPSell20,000$17.30$346,000.00View SEC Filing  
1/6/2015Krisztina M ZseboCEOSell41,302$17.51$723,198.02View SEC Filing  
1/2/2015Ryan K TakeyaVPSell7,777$19.88$154,606.76View SEC Filing  
12/9/2014Jeffrey J RudyVPSell10,000$15.00$150,000.00View SEC Filing  
12/9/2014Krisztina M ZseboCEOSell41,302$15.00$619,530.00View SEC Filing  
12/5/2014Rebecque J LabaVPSell20,000$12.77$255,400.00View SEC Filing  
12/1/2014Ryan K TakeyaVPSell7,777$12.01$93,401.77View SEC Filing  
2/4/2014Enterprise Partners ManagementMajor ShareholderBuy133,083$8.00$1,064,664.00View SEC Filing  
2/4/2014Fredrik WiklundVPBuy20,000$8.00$160,000.00View SEC Filing  
2/4/2014Todd FoleyDirectorBuy111,608$8.00$892,864.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eiger Biopharmaceuticals (NASDAQ EIGR) News Headlines

Source:
DateHeadline
Eigers lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2%Eiger's lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2%
seekingalpha.com - April 18 at 8:16 AM
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib ...Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib ...
www.prnewswire.com - April 17 at 5:54 PM
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
finance.yahoo.com - April 17 at 5:54 PM
Zacks: Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Announce -$1.00 EPSZacks: Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Announce -$1.00 EPS
www.americanbankingnews.com - April 16 at 7:11 AM
Eiger Biopharmaceuticals Inc. (EIGR) Given Consensus Rating of "Buy" by BrokeragesEiger Biopharmaceuticals Inc. (EIGR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 15 at 8:19 AM
Eiger Biopharmaceuticals (EIGR) Rating Increased to Buy at ValuEngineEiger Biopharmaceuticals (EIGR) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 13 at 11:10 PM
Eiger Biopharmaceuticals (EIGR) Upgraded to Hold by Zacks Investment ResearchEiger Biopharmaceuticals (EIGR) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 12 at 5:09 PM
Critical Survey: Bavarian Nordic (BVNRY) and Eiger Biopharmaceuticals (EIGR)Critical Survey: Bavarian Nordic (BVNRY) and Eiger Biopharmaceuticals (EIGR)
www.americanbankingnews.com - April 12 at 3:15 PM
Eiger Biopharmaceuticals (EIGR) Given Buy Rating at Piper JaffrayEiger Biopharmaceuticals (EIGR) Given Buy Rating at Piper Jaffray
www.americanbankingnews.com - April 10 at 12:01 PM
Eiger Biopharmaceuticals Inc. (EIGR) Insider Sells $40,000.00 in StockEiger Biopharmaceuticals Inc. (EIGR) Insider Sells $40,000.00 in Stock
www.americanbankingnews.com - April 4 at 11:37 PM
Eiger Biopharmaceuticals (EIGR) Raised to Hold at ValuEngineEiger Biopharmaceuticals (EIGR) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM
Eiger BioPharmaceuticals to Participate in Conferences in AprilEiger BioPharmaceuticals to Participate in Conferences in April
finance.yahoo.com - April 2 at 8:40 AM
Eiger Biopharmaceuticals (EIGR) Raised to "Hold" at ValuEngineEiger Biopharmaceuticals (EIGR) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM
 Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Post -$1.00 Earnings Per Share Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Post -$1.00 Earnings Per Share
www.americanbankingnews.com - March 30 at 11:30 AM
What Should We Expect From Eiger BioPharmaceuticals Inc’s (NASDAQ:EIGR) Earnings In The Next Couple Of Years?What Should We Expect From Eiger BioPharmaceuticals Inc’s (NASDAQ:EIGR) Earnings In The Next Couple Of Years?
finance.yahoo.com - March 30 at 8:23 AM
Eiger Biopharmaceuticals (EIGR) Given "Overweight" Rating at Piper JaffrayEiger Biopharmaceuticals (EIGR) Given "Overweight" Rating at Piper Jaffray
www.americanbankingnews.com - March 28 at 12:58 PM
Eiger Biopharmaceuticals (EIGR) Given a $26.00 Price Target by Oppenheimer AnalystsEiger Biopharmaceuticals (EIGR) Given a $26.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - March 28 at 12:58 PM
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric HypoglycemiaEiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
finance.yahoo.com - March 26 at 8:22 AM
Wedbush Comments on Eiger Biopharmaceuticals Inc.s FY2022 Earnings (EIGR)Wedbush Comments on Eiger Biopharmaceuticals Inc.'s FY2022 Earnings (EIGR)
www.americanbankingnews.com - March 26 at 1:54 AM
Eiger BioPharmaceuticals (EIGR) Reports Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration ProgramEiger BioPharmaceuticals (EIGR) Reports Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
www.streetinsider.com - March 23 at 5:42 PM
Eiger Biopharmaceuticals (EIGR) Upgraded at Zacks Investment ResearchEiger Biopharmaceuticals (EIGR) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 22 at 9:48 PM
Eiger Biopharmaceuticals (EIGR) Stock Rating Reaffirmed by WedbushEiger Biopharmaceuticals (EIGR) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - March 22 at 2:26 PM
Brokers Offer Predictions for Eiger Biopharmaceuticals Inc.s Q1 2018 Earnings (EIGR)Brokers Offer Predictions for Eiger Biopharmaceuticals Inc.'s Q1 2018 Earnings (EIGR)
www.americanbankingnews.com - March 22 at 8:45 AM
Eiger Biopharmaceuticals (EIGR) Given Buy Rating at OppenheimerEiger Biopharmaceuticals (EIGR) Given Buy Rating at Oppenheimer
www.americanbankingnews.com - March 21 at 1:56 PM
Eiger Biopharmaceuticals Inc (EIGR) Given Average Rating of "Buy" by BrokeragesEiger Biopharmaceuticals Inc (EIGR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 21 at 11:32 AM
Eiger BioPharmaceuticals (EIGR) Reports Positive Guidance Following FDA Meeting on Hepatitis Delta Virus ... - StreetInsider.comEiger BioPharmaceuticals (EIGR) Reports Positive Guidance Following FDA Meeting on Hepatitis Delta Virus ... - StreetInsider.com
www.streetinsider.com - March 21 at 8:48 AM
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration ProgramEiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
finance.yahoo.com - March 21 at 8:48 AM
Eiger Biopharmaceuticals (EIGR) Given a $26.00 Price Target at OppenheimerEiger Biopharmaceuticals (EIGR) Given a $26.00 Price Target at Oppenheimer
www.americanbankingnews.com - March 18 at 12:26 PM
Eiger Biopharmaceuticals (EIGR) Lowered to "Sell" at Zacks Investment ResearchEiger Biopharmaceuticals (EIGR) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 15 at 9:26 PM
Research Analysts Issue Forecasts for Eiger Biopharmaceuticals Incs FY2018 Earnings (EIGR)Research Analysts Issue Forecasts for Eiger Biopharmaceuticals Inc's FY2018 Earnings (EIGR)
www.americanbankingnews.com - March 15 at 9:22 AM
Research Analysts Issue Forecasts for Eiger Biopharmaceuticals Incs Q1 2018 Earnings (EIGR)Research Analysts Issue Forecasts for Eiger Biopharmaceuticals Inc's Q1 2018 Earnings (EIGR)
www.americanbankingnews.com - March 14 at 8:44 AM
Eiger Biopharmaceuticals (EIGR) to Release Earnings on WednesdayEiger Biopharmaceuticals (EIGR) to Release Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:16 AM
Eiger Biopharmaceuticals (EIGR) Releases  Earnings Results, Misses Estimates By $0.09 EPSEiger Biopharmaceuticals (EIGR) Releases Earnings Results, Misses Estimates By $0.09 EPS
www.americanbankingnews.com - March 13 at 10:39 AM
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results - PR Newswire (press release)Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 13 at 8:25 AM
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsEiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 6:39 PM
Eiger (EIGR) Announces Abstracts, Presentations of LOWR HDV Program and Planned Registration Program at Liver Congress MeetingEiger (EIGR) Announces Abstracts, Presentations of LOWR HDV Program and Planned Registration Program at Liver Congress Meeting
www.streetinsider.com - March 6 at 5:40 PM
Stonepine Capital Management LLC Takes $2.09 Million Position in Eiger Biopharmaceuticals Inc (EIGR)Stonepine Capital Management LLC Takes $2.09 Million Position in Eiger Biopharmaceuticals Inc (EIGR)
www.americanbankingnews.com - March 6 at 10:02 AM
Eiger BioPharmaceuticals to Participate in US and International Investor and Partnership Conferences in March - PR Newswire (press release)Eiger BioPharmaceuticals to Participate in US and International Investor and Partnership Conferences in March - PR Newswire (press release)
www.prnewswire.com - March 6 at 8:15 AM
Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in MarchEiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March
finance.yahoo.com - March 6 at 8:15 AM
Prosight Management LP Invests $9.47 Million in Eiger Biopharmaceuticals Inc (EIGR)Prosight Management LP Invests $9.47 Million in Eiger Biopharmaceuticals Inc (EIGR)
www.americanbankingnews.com - March 5 at 2:54 PM
Eiger (EIGR) Announces Abstracts, Presentations of LOWR HDV Program and Planned Registration Program at Liver ... - StreetInsider.comEiger (EIGR) Announces Abstracts, Presentations of LOWR HDV Program and Planned Registration Program at Liver ... - StreetInsider.com
www.streetinsider.com - March 5 at 8:17 AM
Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ MeetingEiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
finance.yahoo.com - March 5 at 8:17 AM
Eiger Biopharmaceuticals (EIGR) Downgraded by ValuEngine to "Strong Sell"Eiger Biopharmaceuticals (EIGR) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - March 4 at 7:16 PM
Eiger Biopharmaceuticals Inc (EIGR) Given Consensus Rating of "Buy" by BrokeragesEiger Biopharmaceuticals Inc (EIGR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 24 at 7:24 AM
Eiger Biopharmaceuticals (EIGR) Lowered to Hold at Zacks Investment ResearchEiger Biopharmaceuticals (EIGR) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 20 at 10:40 PM
Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in FebruaryEiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
finance.yahoo.com - February 6 at 9:28 AM
Comparing Jaguar Health (JAGX) & Eiger Biopharmaceuticals (EIGR)Comparing Jaguar Health (JAGX) & Eiger Biopharmaceuticals (EIGR)
www.americanbankingnews.com - February 4 at 5:16 AM
 Analysts Expect Eiger Biopharmaceuticals Inc (EIGR) Will Post Earnings of -$1.02 Per Share Analysts Expect Eiger Biopharmaceuticals Inc (EIGR) Will Post Earnings of -$1.02 Per Share
www.americanbankingnews.com - January 21 at 11:26 AM
These Two Biotechs Just Reported Key DataThese Two Biotechs Just Reported Key Data
finance.yahoo.com - January 19 at 10:29 AM
Eiger BioPharmaceuticals Inc. (EIGR) Is Sinking After Phase 2 Study FailedEiger BioPharmaceuticals Inc. (EIGR) Is Sinking After Phase 2 Study Failed
www.nasdaq.com - January 16 at 5:22 PM

SEC Filings

Eiger Biopharmaceuticals (NASDAQ:EIGR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eiger Biopharmaceuticals (NASDAQ:EIGR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eiger Biopharmaceuticals (NASDAQ EIGR) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.